Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.28 USD | +1.86% | -0.30% | +62.38% |
May. 10 | Leerink Partners Starts Aquestive Therapeutics With Outperform Rating, $8 Price Target | MT |
May. 08 | Transcript : Aquestive Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024 |
Financials (USD)
Sales 2024 * | 50.02M | Sales 2025 * | 58.76M | Capitalization | 299M |
---|---|---|---|---|---|
Net income 2024 * | -45M | Net income 2025 * | -37M | EV / Sales 2024 * | 5.92 x |
Net cash position 2024 * | 2.63M | Net Debt 2025 * | 15.47M | EV / Sales 2025 * | 5.34 x |
P/E ratio 2024 * |
-6.05
x | P/E ratio 2025 * |
-7.9
x | Employees | 135 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.07% |
Latest transcript on Aquestive Therapeutics, Inc.
1 day | +1.86% | ||
1 week | -0.30% | ||
Current month | -2.38% | ||
1 month | -14.81% | ||
3 months | +21.71% | ||
6 months | +90.70% | ||
Current year | +62.38% |
Managers | Title | Age | Since |
---|---|---|---|
Daniel Barber
CEO | Chief Executive Officer | 48 | 07-06-30 |
A. Toth
DFI | Director of Finance/CFO | 65 | 20-12-30 |
Stephen Wargacki
CTO | Chief Tech/Sci/R&D Officer | 46 | 14-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Timothy Morris
BRD | Director/Board Member | 61 | 22-08-09 |
Santo Costa
BRD | Director/Board Member | 78 | 15-11-30 |
Gregory Brown
CHM | Chairman | 70 | 07-02-28 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-16 | 3.28 | +1.86% | 628,406 |
24-05-15 | 3.22 | +0.63% | 941,661 |
24-05-14 | 3.2 | -2.14% | 1,125,453 |
24-05-13 | 3.27 | +5.83% | 1,501,618 |
24-05-10 | 3.09 | -6.08% | 2,032,874 |
Delayed Quote Nasdaq, May 16, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+62.38% | 293M | |
+32.36% | 709B | |
+30.77% | 595B | |
-1.60% | 367B | |
+20.07% | 334B | |
+6.04% | 289B | |
+14.77% | 239B | |
+9.13% | 211B | |
-3.97% | 203B | |
+9.27% | 171B |
- Stock Market
- Equities
- AQST Stock